Objective It is to explore the curative effect and safety of Qianggan capsule in treating for patients with chronic hepatitis B with hepatic fibrosis. Methods 258 patients with chronic hepatitis B with hepatic fibrosis were enrolled and randomly divided into control group and treatment group. Both of the groups were given normal therapy, and the treatment group was added with Qainggan capsule. After 6 months'treatment, the clinical curative effect, hepatic function, spectrum of liver fibrosis and adverse reaction in both groups were observed. Results The total effective rate was 92% in treatment group, which was obviously higher than that of control group (75% ). The levels of TBil, ALT, AST in both groups were decreased after treatment, and that of ALB was increased more or less; The decreasing levels of TBil, ALT, AST in the treatment group were more than those of control group. The serum markers of hepatic fibrosis in both groups dropped much, and the decreasing degrees especially HA, PC Ⅲ and LN were more obviously in treatment group than that in control group. The levels of TGF -β1, TIMP -1 were significantly decreased and MMP - 1 was markedly increased in both groups after 6 months'treatment, and the improvements in treatment group were better. There was no obvious bad effect in both groups. Conclusion Qianggan capsule not only can improve the clinical symptoms and hepatic function, but also can obviously improve hepatic fibrosis, it is a satisfactory drug in the treatment for chronic hepatitis B with hepatic fibrosis.%目的 探讨强肝胶囊治疗乙型肝炎肝纤维化的疗效以及安全性.方法 将乙型肝炎肝纤维化患者258例随机分为2组:2组均给予常规治疗,治疗组加用强肝胶囊,治疗6个月后观察临床治疗效果,肝功能、肝纤维化情况及不良反应发生情况.结果 治疗组总有效率(92％)明显高于对照组(75％).治疗后2组血清总胆红素(TBil)、血清丙氨酸氨基转移酶(ALT)、血清门冬氨酸氨基转移酶(AST)均较治疗前明显降低,白蛋白(ALB)不同程度升高;治疗组治疗后TBil、ALT、AST降低较对照组明显;2组患者治疗后肝纤维化血清学指标均下降,治疗组降低较对照组更为明显,特别是HA、PCⅢ和LN;治疗6个月后,2组TGF-β1、TIMP-1水平均较治疗前显著下降,MMP-1水平较治疗前显著升高,且治疗组TGF-β1、TIMP-1和MMP-1改善情况均优于对照组.治疗组不良反应轻微,不影响治疗.结论 强肝胶囊不仅可改善患者临床症状及肝功能,而且具有明显改善肝脏纤维化程度的作用,是治疗乙型肝炎肝纤维化的有效药物之一.
展开▼
